Partial normalization of pubertal timing in female mice with DSS colitis treated with anti-TNF-α antibody

Journal of Gastroenterology

Volumn 47, Issue 6, 2012, Pages 647-654

  DeBoer, Mark Daniel ^a   Steinman, Jeremy ^a   Li, Yongli ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Colitis; Inflammation; Puberty; TNF

Indexed keywords

FOLLITROPIN; GONADORELIN; INFLIXIMAB; INTERLEUKIN 6; LUTEINIZING HORMONE; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY GROWTH; COLITIS; CONTROLLED STUDY; FEMALE; FEMALE GENITAL SYSTEM FUNCTION; FOOD INTAKE; HISTOLOGY; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PUBERTY; SCORING SYSTEM; VAGINA OPENING; WEIGHT GAIN;

ANIMALS; ANTIBODIES, MONOCLONAL; COLITIS; DEXTRAN SULFATE; DRUG EVALUATION, PRECLINICAL; EATING; FEMALE; FOLLICLE STIMULATING HORMONE; GASTROINTESTINAL AGENTS; GROWTH; LUTEINIZING HORMONE; MICE; MICE, INBRED C57BL; PUBERTY, DELAYED; TUMOR NECROSIS FACTOR-ALPHA; VAGINA; WEIGHT GAIN;

EID: 84865120346     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-012-0542-y     Document Type: Article

References (33)

1. Ballinger AB, Savage MO, Sanderson IR. Delayed puberty associated with inflammatory bowel disease. Pediatr Res. 2003; 53:205-10. (Pubitemid 36177114)
2. Pfefferkorn M, Burke G, Griffiths A, Markowitz J, Rosh J, Mack D, Otley A, Kugathasan S, Evans J, Bousvaros A, Moyer MS, Wyllie R, Oliva-Hemker M, Carvalho R, Crandall W, Keljo D, Walters TD, LeLeiko N, Hyams J. Growth abnormalities persist in newly diagnosed children with Crohn disease despite current treatment paradigms. J Pediatr Gastroenterol Nutr. 2009;48: 168-74.
3. Sawczenko A, Ballinger AB, Savage MO, Sanderson IR. Clinical features affecting final adult height in patients with pediatric-onset Crohn's disease. Pediatrics. 2006;118:124-9. (Pubitemid 46071155)
4. Wong SC, Macrae VE, McGrogan P, Ahmed SF. The role of pro-inflammatory cytokines in inflammatory bowel disease growth retardation. J Pediatr Gastroenterol Nutr. 2006;43:144-55. (Pubitemid 44180496)
5. DeBoer MD, Barnes BH. The importance of treatment regimens and pubertal status for growth in IBD. J Pediatr. 2009;154:936-7.
6. Dubner SE, Shults J, Baldassano RN, Zemel BS, Thayu M, Burnham JM, Herskovitz RM, Howard KM, Leonard MB. Longitudinal assessment of bone density and structure in an incident cohort of children with Crohn's disease. Gastroenterology. 2009; 136:123-30.
7. Paganelli M, Albanese C, Borrelli O, Civitelli F, Canitano N, Viola F, Passariello R, Cucchiara S. Inflammation is the main determinant of low bone mineral density in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:416-23. (Pubitemid 46668246)
8. Thayu M, Leonard MB, Hyams JS, Crandall WV, Kugathasan S, Otley AR, Olson A, Johanns J, Marano CW, Heuschkel RB, Veereman-Wauters G, Griffiths AM, Baldassano RN. Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study. Clin Gastroenterol Hepatol. 2008;6:1378-84.
9. Azooz OG, Farthing MJ, Savage MO, Ballinger AB. Delayed puberty and response to testosterone in a rat model of colitis. Am J Physiol Regul Integr Comp Physiol. 2001;281:R1483-91.
10. Farooqi IS. Leptin and the onset of puberty: insights from rodent and human genetics. Semin Reprod Med. 2002;20:139-44. (Pubitemid 34764278)
11. Kaminski BA, Palmert MR. Genetic control of pubertal timing. Curr Opin Pediatr. 2008;20:458-64.
12. Kalra PS, Sahu A, Kalra SP. Interleukin-1 inhibits the ovarian steroid-induced luteinizing hormone surge and release of hypo-thalamic luteinizing hormone-releasing hormone in rats. Endocrinology. 1990;126:2145-52. (Pubitemid 20139765)
13. Rivier C, Vale W. Cytokines act within the brain to inhibit luteinizing hormone secretion and ovulation in the rat. Endocrinology. 1990;127:849-56. (Pubitemid 20248131)
14. Nappi RE, Rivest S. Effect of immune and metabolic challenges on the luteinizing hormone-releasing hormone neuronal system in cycling female rats: an evaluation at the transcriptional level. Endocrinology. 1997;138:1374-84. (Pubitemid 27137082)
15. DeBoer MD, Li Y. Puberty is delayed in male mice with dextran sodium sulfate colitis out of proportion to changes in food intake, body weight, and serum levels of leptin. Pediatr Res. 2011;69: 34-9.
16. DeBoer MD, Li Y, Cohn S. Colitis causes delay in puberty in female mice out of proportion to changes in leptin and cortico-sterone. J Gastroenterol. 2010;45:277-84.
17. Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenter-ology. 2007;132:863-73. (quiz 1165-1166). (Pubitemid 46454266)
18. Sinitsky DM, Lemberg DA, Leach ST, Bohane TD, Jackson R, Day AS. Infliximab improves inflammation and anthropometric measures in pediatric Crohn's disease. J Gastroenterol Hepatol. 2010; 25:810-6.
19. Walters TD, Gilman AR, Griffiths AM. Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease. Inflamm Bowel Dis. 2007;13:424-30. (Pubitemid 46668247)
20. Nelson JF, Karelus K, Felicio LS, Johnson TE. Genetic influences on the timing of puberty in mice. Biol Reprod. 1990;42:649-55. (Pubitemid 20168885)
21. Burns RC, Rivera-Nieves J, Moskaluk CA, Matsumoto S, Com-inelli F, Ley K. Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn's disease in mice. Gastroenterology. 2001;121: 1428-36. (Pubitemid 33140460)
22. Marini M, Bamias G, Rivera-Nieves J, Moskaluk CA, Hoang SB, Ross WG, Pizarro TT, Cominelli F. TNF-alpha neutralization ameliorates the severity of murine Crohn's-like ileitis by abrogation of intestinal epithelial cell apoptosis. Proc Natl Acad Sci USA. 2003;100:8366-71. (Pubitemid 36842551)
23. Bland JM, Altman DG. The logrank test. BMJ. 2004;328:1073.
24. Eckert KL, Wilson DM, Bachrach LK, Anhalt H, Habiby RL, Olney RC, Hintz RL, Neely EK. A single-sample, subcutaneous gonadotropin-releasing hormone test for central precocious puberty. Pediatrics. 1996;97:517-9. (Pubitemid 26098300)
25. DeBoer MD, Marks DL. Therapy insight: use of melanocortin antagonists in the treatment of cachexia in chronic disease. Nat Clin Pract Endocrinol Metab. 2006;2:459-66. (Pubitemid 44214068)
26. Kojouharoff G, Hans W, Obermeier F, Mannel DN, Andus T, Scholmerich J, Gross V, Falk W. Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin Exp Immunol. 1997;107:353-8. (Pubitemid 27049264)
27. Bento AF, Leite DF, Claudino RF, Hara DB, Leal PC, Calixto JB. The selective nonpeptide CXCR2 antagonist SB225002 ameliorates acute experimental colitis in mice. J Leukoc Biol. 2008;84: 1213-21.
28. Wong ML, Bongiorno PB, Rettori V, McCann SM, Licinio J. Interleukin (IL) 1beta, IL-1 receptor antagonist, IL-10, and IL-13 gene expression in the central nervous system and anterior pituitary during systemic inflammation: pathophysiological implications. Proc Natl Acad Sci USA. 1997;94:227-32. (Pubitemid 27027191)
29. Marshall JC, Kelch RP. Gonadotropin-releasing hormone: role of pulsatile secretion in the regulation of reproduction. N Engl J Med. 1986;315:1459-68. (Pubitemid 17051707)
30. Malik S, Wong SC, Bishop J, Hassan K, McGrogan P, Ahmed SF, Russell RK. Improvement in growth of children with Crohn disease following anti-TNF-alpha therapy can be independent of pubertal progress and glucocorticoid reduction. J Pediatr Gas-troenterol Nutr. 2011;52:31-7.
31. Bernstein M, Irwin S, Greenberg GR. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease. Am J Gastroenterol. 2005;100:2031-5.
32. DeBoer MD, Barnes BH, Stygles NA, Sutphen JL, Borowitz SM. Changes in inflammation and quality of life after a single dose of infliximab during on-going treatment: Differences between patients with and without IBD symptoms at time of administration. J Pediatr Gastroenterol Nutr. 2011. doi:10.1097/MPG.0b 013e3182382ee3
33. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Inflix-imab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-76. (Pubitemid 41770166)